Entera Bio and Altimmune both add directors in late-October board moves

Entera Bio Ltd. said on October 27, 2026 that it had appointed Juan Camilo Arjona Ferreira, M.D., to its board of directors, effective December 1, 2026, with his appointment coming as Ms. Haya Taitel steps down from the board.¹ Dr. Arjona Ferreira is Head of Research & Development and Chief Medical Officer at Organon & Co. (NYSE: OGN), where he leads the company's global R&D organization covering early- and late-stage development, regulatory affairs, pharmacovigilance and medical affairs with a focus on women's health.¹ Earlier in his career he was Chief Medical Officer at Myovant Sciences, Senior Vice President of Clinical Development at Shionogi, and spent over a decade at Merck, finishing as Executive Director of Clinical Research in Women's Health.¹ He will also serve on the compensation committee of the board, effective December 1, 2026.¹

Separately, Altimmune, Inc. announced on October 27, 2026 that Peter Greenleaf and Alex Howarth would join its board of directors effective November 2, 2026, which increases board size from nine to eleven directors.² The move accompanies a leadership transition in which John Gill, Mitchell Sayare and Dr. Klaus Schafer have notified the board they will retire and not stand for reelection at the 2027 Annual Meeting, continuing to serve until that meeting.² Greenleaf most recently served as CEO and board member of Aurinia Pharmaceuticals² and currently chairs the board of Pelthos Therapeutics and sits on the board of Revolo Biotherapeutics.² Howarth most recently served as CFO of Madrigal Pharmaceuticals from May 2021 through May 2024.² Each new director will receive an initial option grant to purchase 160,000 shares and an annual cash retainer of $40,000.²